The long term objectives are to develop a novel treatment for human lupus that has fewer side effects than currently available immunosuppressive treatment and has improved efficacy. To this end, we have used a pre-clinical model of lupus and demonstrated that immunomodulation, i.e. skewing of the immune response away from antibody production and enhancing cell mediated immunity to include cytotoxic T lymphocytes is both feasible and beneficial in this model. The current proposal also demonstrates that lupus predisposition may relate to a pre-existing defect in interleukin-2 which promotes immune skewing. Using in vivo and vitro approaches combined with flow cytometry, genetic analysis and cellular immunology, this proposal has the following aims: 1) use pre-clinical models to determine whether defective T cell production of IL-2 predisposes to lupus, the mechanism by which this occurs, whether IL-2 replacement will be beneficial and adapt the murine approach to screen human lupus patients for similar abnormalities;2) develop non IL-2 based immunomodulatory approaches (e.g., TLR stimulants) and test their efficacy in several murine models;3) define the mechanism(s) that mediate sex differences in lupus severity in a murine model. These studies will provide novel insights into the role of IL-2 in lupus pathogenesis and identify new, non-immunosuppressive therapeutic approaches to lupus treatment.
This proposal addresses a novel form of potential treatment for lupus and identifies a potential cause of lupus predisposition i.e. defective interleukin-2 production. Unlike current therapeutic approaches that involve immune suppression, this approach uses interleukin -2 and non- interleukin-2 based approaches to modulate the immune response and skew it away from autoantibody production and toward cell mediated immunity.
|Soloviova, Kateryna; Puliaiev, Maksym; Puliaev, Roman et al. (2018) Both perforin and FasL are required for optimal CD8 T cell control of autoreactive B cells and autoantibody production in parent-into-F1 lupus mice. Clin Immunol 194:34-42|
|Via, Charles S; Soloviova, Kateryna; Puliaiev, Maksym et al. (2017) In vivo IL-4 prevents allo-antigen driven CD8+ CTL development. Clin Immunol 180:11-24|
|Soloviova, Kateryna; Puliaiev, Maksym; Haas, Mark et al. (2015) Intrinsic Differences in Donor CD4 T Cell IL-2 Production Influence Severity of Parent-into-F1 Murine Lupus by Skewing the Immune Response Either toward Help for B Cells and a Sustained Autoantibody Response or toward Help for CD8 T Cells and a Downregula J Immunol 195:2985-3000|
|Puliaeva, Irina; Soloviova, Kateryna; Puliaiev, Maksym et al. (2011) Enhancement of suboptimal CD8 cytotoxic T cell effector function in vivo using antigen-specific CD80 defective T cells. J Immunol 186:291-304|
|Via, Charles S (2011) Pre-clinical screening of immunomodulatory compounds using the parent-into-F1 model. Clin Immunol 140:212-5|